TABLE 2.
Fungal burden in the lungs and spleen of mice that survived to day 17 after infection with 5 × 105 CFU of H. capsulatum (isolate 2; nikkomycin Z MIC, 4 μg/ml)
| Drug and dose (mg/kg) | n | Antigen (EU) median (range)
|
Quantitative culture median (CFU/g of organ weight)
|
||
|---|---|---|---|---|---|
| Lung | Spleen | Lung | Spleen | ||
| Amphotericin B (2.0) | 10 | 2.9a (2.5–6.4) | 1.2a (0.9–5.1) | 0a | 0 |
| Itraconazole (75) | 10 | 4.2a (1.7–5.9) | 1.7a (0.8–2.0) | 3.3 × 102a,b,c | 7.5 × 102b,c |
| Nikkomycin Z (100) | 7 | 3.2a (1.7–3.4) | 1.2a (0.9–1.8) | NEf | 0d |
| Nikkomycin Z (20) | 8 | 2.9a (2.5–5.0) | 1.4a (1.0–2.8) | 1.1 × 103b,e | 6.4 × 102b,e |
| Nikkomycin Z (5) | 8 | 3.8 (3.4–4.4) | 2.5b (2.0–5.9) | NE | NE |
| Control | 3 | 13.6 (12.4–14.1) | 13.4 (11.8–14.0) | 9.0 × 105b | NE |
a
P < 0.05 in comparison to untreated controls.
b
P < 0.05 in comparison to mice treated with amphotericin B.
c
Eight of ten mice evaluable for lung homogenates; 9 of 10 mice evaluable for spleen homogenates.
d
Five of seven mice evaluable for spleen homogenates.
e
Two of eight mice evaluable for lung homogenates; 4 of 8 mice evaluable for spleen homogenates.
f
NE, nonevaluable due to either overdilution of homogenates or bacterial contamination of plates.